⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

BBIO News

BridgeBio Pharma, Inc. Common Stock

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM